A panel of government advisers recommended on a 10-5 vote Thursday that Johnson & Johnson’s (NYSE:JNJ) experimental diabetes drug Invokana should be approved by the Food and Drug Administration. The vote is a win for J&J as it hopes to get clearance for its first prescription drug for diabetes. The company conducted a massive study of more than 10 000 people to show the benefits of the medicine. On a separate vote the panelists were split 8-7 on whether the company provided evidence that Invokana’s risk of heart attack stroke and other cardiovascular events is acceptable under FDA guidelines. ...